Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Article Details
- CitationCopy to clipboard
Clark MP, George KM, Bookland RG, Chen J, Laughlin SK, Thakur KD, Lee W, Davis JR, Cabrera EJ, Brugel TA, VanRens JC, Laufersweiler MJ, Maier JA, Sabat MP, Golebiowski A, Easwaran V, Webster ME, De B, Zhang G
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Bioorg Med Chem Lett. 2007 Mar 1;17(5):1250-3. Epub 2006 Dec 9.
- PubMed ID
- 17189692 [ View in PubMed]
- Abstract
A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.